Gold prices dip as hawkish Fed minutes weigh ahead of Jackson Hole
AMSTERDAM—Christian Klemt, Chief Financial Officer of uniQure N.V. (NASDAQ:QURE), recently executed multiple transactions involving the company’s ordinary shares. According to a recent SEC filing, Klemt sold shares in two separate transactions, totaling over $186,000. The transactions come as InvestingPro data shows the stock has demonstrated significant volatility, with a remarkable 106% surge over the past six months despite recent market pressures.
On February 25, Klemt sold 14,341 shares at an average price of $10.70, generating approximately $153,448. This sale was conducted to cover estimated withholding taxes upon the vesting of restricted share units, as per automatic sale instructions, and was not a discretionary trade.
Following this, on February 27, Klemt sold an additional 2,916 shares at an average price of $11.32, amounting to about $33,009. Like the previous transaction, this sale was also made to cover withholding taxes upon the vesting of performance-based restricted share units.
In between these sales, on February 26, Klemt acquired 5,712 performance-based restricted share units, which were granted under the company’s 2014 Share Incentive Plan. These units were earned as a result of meeting certain performance criteria and were acquired at no cost.
After these transactions, Klemt’s direct ownership in uniQure stands at 155,168 shares. According to InvestingPro analysis, the company appears undervalued based on its Fair Value model, despite trading at elevated revenue multiples. InvestingPro subscribers have access to 13 additional key insights about uniQure’s financial health and market position.
In other recent news, CSL (OTC:CSLLY) Behring has confirmed the long-term efficacy and safety of HEMGENIX, a gene therapy for hemophilia B, based on four-year results from the HOPE-B study. The treatment has shown sustained factor IX activity levels and a significant reduction in annualized bleeding rates, with no patients returning to continuous prophylaxis between the third and fourth years. Meanwhile, uniQure has completed enrollment for the first cohort in its Phase I/IIa trial of AMT-191, a gene therapy for Fabry disease, and plans to proceed with dosing the second cohort following a positive safety assessment. In addition, H.C. Wainwright has raised its price target for uniQure to $70, maintaining a Buy rating, citing optimism about the company’s AMT-130 program for Huntington’s disease. uniQure also announced the pricing of a public offering of shares, expecting to raise approximately $75 million, with the offering anticipated to close in January 2025. Furthermore, TD Cowen has highlighted uniQure’s plans to submit an accelerated approval application for AMT-130 in Huntington’s disease as a key catalyst for 2025. These developments reflect the ongoing advancements and strategic financial maneuvers within the biotechnology sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.